Protocol Ledger

NCT06931340 · Phase III · RECRUITING

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Interventional Phase III clinical trial protocol NCT06931340 sponsored by Alliance for Clinical Trials in Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-01 Enrollment: 1,260 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06931340
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,260 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06931340
Protocol FieldVerified Registry Value
NCT IdentifierNCT06931340
Consolidated Lead SponsorAlliance for Clinical Trials in Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,260 participants (ESTIMATED)
Registered Start Date2025-12-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI